NEW YORK A pickup in new drug approvals, the promise of faster regulatory decisions and more targeted medicines have quickened the pulse of the pharmaceutical industry as a big wave of patent expiries recedes.
NEW YORK Big data is emerging as a big headache for the drug industry as regulators and advocates push for greater transparency on information from clinical trials, leaving companies split over how to respond.
NEW YORK A novel device by Medtronic Inc to relieve high blood pressure faces an uphill battle in Europe, where cash-strapped government health plans are reluctant to pay for an innovation they do not understand well, the company's chief executive said.
NEW YORK Biotechnology companies that just a short time ago were viewed as takeover targets are now more likely to be buyers themselves after seeing their valuations soar on promising new drugs.
NEW YORK Europe must start paying more for new medicines and take some of the cost burden of supporting pharmaceutical drug development off the United States, Novo Nordisk's Chief Executive Lars Sorensen said.
NEW YORK A federal judge criticized the Food and Drug Administration over its refusal to make emergency contraception available to girls of all ages without a prescription, saying the agency's move to restrict distribution to consumers aged 15 and older was not realistic.
NEW YORK Novo Nordisk's long-term profit targets are hanging in the balance after a big setback in the U.S. market but the Danish drugmaker may yet hit its goal if things work out for one of two drugs, its CEO said.
NEW YORK America's budget cuts may be beginning to take a toll on the public health system, from efforts to track global flu outbreaks to policing a surge in food and drug imports.
NEW YORK Tenet Healthcare Corp sees its hospitals playing a role in signing up uninsured Americans for President Barack Obama's healthcare overhaul, particularly in states that are balking at implementing the reform.
NEW YORK Tenet Healthcare Corp is eyeing growth through acquisitions or partnerships in regions where it already has a presence and would consider buying a larger system to gain entry into a new geographic market, its chief executive said on Tuesday.
NEW YORK A new generation of drug industry chief executives is stepping up plans to restructure their businesses by divesting slower-growing and maturing operations, opening up new opportunities for deal-makers.